Table 4.

Clinical Outcomes Based on Early Regression of Severe LVH after TAVR

Clinical Outcome	Greater LVMi Regression % (no.)	Lesser LVMi Regression % (no.)	Hazard Ratio (95% CI)	p-value
Outcomes 30 days to 1 year Combined	n=344	n=346
Death (all-cause)	14.1% (47)	14.3% (48)	1.00 [0.67,1.49]	0.99
Death (cardiac)	8.8% (28)	9.3% (30)	0.95 [0.57,1.59]	0.84
Repeat hospitalizations	9.5% (30)	18.5% (59)	0.50 [0.32,0.78]	0.002
Hospitalizations for CHF	7.3% (23)	13.6% (43)	0.53 [0.32,0.88]	0.01
Death or hospitalizations	19.4% (65)	27.1% (91)	0.70 [0.51,0.97]	0.03
Stroke (any)	1.3% (4)	1.6% (5)	0.81 [0.22,3.03]	0.76
Outcomes 30 days to 1 year Males	n=151	n=152
Death (all-cause)	18.4% (27)	20.0% (29)	0.94 [0.55,1.58]	0.81
Death (cardiac)	10.9% (15)	13.1% (18)	0.83 [0.42,1.66]	0.60
Repeat hospitalizations	13.6% (19)	23.3% (32)	0.57 [0.32,1.01]	0.051
Death or hospitalizations	24.4% (36)	35.5% (52)	0.67 [0.44,1.02]	0.059
Stroke (any)	1.5% (2)	0.7% (1)	2.03 [0.18,22.43]	0.55
Outcomes 30 days to 1 year Females	n=193	n=194
Death (all-cause)	10.7% (20)	9.9% (19)	1.07 [0.57,2.00]	0.83
Death (cardiac)	7.2% (13)	6.4% (12)	1.10 [0.50,2.42]	0.81
Repeat hospitalizations	6.2% (11)	15.0% (27)	0.40 [0.20,0.81]	0.009
Death or hospitalizations	15.5% (29)	20.6% (39)	0.74 [0.46,1.19]	0.21
Stroke (any)	1.1% (2)	2.3% (4)	0.51 [0.09,2.78]	0.43
Outcomes 0–30 days	n=344	n=346
Post-TAVR myocardial infarct	0.9% (3)	0.6% (2)	1.51 [0.25,9.04]	0.65
Major bleeding	5.8% (20)	6.9% (24)	0.83 [0.46,1.51]	0.54
Major vascular complication	5.8% (20)	4.9% (17)	1.18 [0.62,2.26]	0.60
Renal failure requiring dialysis	2.3% (8)	0.9% (3)	2.70 [0.72,10.19]	0.13
Stroke (any)	2.3% (8)	3.5% (12)	0.67 [0.27,1.64]	0.37

Greater vs. lesser LVMi regression defined by sex-specific median % change in LVMi from baseline to 30 days post-TAVR.

The event rates were calculated with the use of Kaplan-Meier methods.

Abbreviations: LVMi, left ventricular mass index; CHF, congestive heart failure; TAVR, transcatheter aortic valve replacement.